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Abstract:	  Infection	   with	   hepatitis	   B	   virus	   (HBV)	   is	   an	   important	   cause	   of	   liver	   disease	   and	   affects	   350	  million	   people	   worldwide,	   causing	   600,000	   deaths/year.	   Treatment	   includes	   interferon	   and	  nucleoside	  analogues	  (NAs)	  such	  as	  lamivudine,	  entecavir,	  and	  tenofovir.	  During	  treatment	  with	  NAs,	  substitutions	  may	  arise	  in	  the	  viral	  genome	  that	  confer	  resistance	  to	  treatment,	  impairing	  or	  abolishing	  the	  effect.	  Clinical	  prognosis	  and	  outcome	  of	  treatment	  are	  affected	  by	  viral	  genotype,	  and	  to	  date	  there	  are	  eight	  established	  (A-­‐H)	  and	  two	  putative	  (I-­‐J)	  genotypes,	  as	  well	  as	  several	  subgenotype	  strains	  described.	  Levels	  of	  viral	  DNA	  and	  surface	  antigen	   (HBsAg)	   in	   serum	  are	  used	   to	  monitor	   the	   course	  of	  infection	  and	  the	  response	  to	  treatment.	  It	  is	  however	  not	  clear	  to	  what	  extent	  mechanisms	  that	  inhibit	   transcription	   of	   the	   pregenomic	   RNA	   (pgRNA),	   contribute	   to	   suppression	   of	   viremia,	  which	  mainly	  occurs	   in	  parallel	  with	   loss	  of	  HBeAg	   from	  blood.	  Likewise,	   it	   is	  unclear	  how	   the	  excessive	  production	  of	  HBsAg	  is	  regulated.	  The	   aims	   of	   this	   thesis	   were	   to	   develop	   methods	   for	   genotyping	   and	   resistance	   mutation	  analysis,	  to	  investigate	  the	  impact	  of	  genotypes	  on	  clinical	  outcome,	  and	  to	  investigate	  the	  role	  of	  the	  regulation	  of	  viral	  transcripts	  for	  replication	  and	  HBsAg	  production.	  Two	  real-­‐time	  PCR	  based	  assays	  were	  designed	  and	  evaluated.	  The	  first	  focused	  on	  amino	  acid	  positions	  180	  and	  204	  in	  the	  viral	  polymerase	  enzyme,	  which	  are	  important	  for	  resistance	  against	  treatment	  with	   the	  NA	   lamivudine.	  The	   second	  aimed	   to	   include	  all	   established	  genotypes	   in	   a	  multiplex	  genotyping	  assay	  for	  accurate	  and	  rapid	  analysis.	  It	  was	  not	  possible	  to	  find	  one	  single	  genomic	  segment	  that	  could	  be	  used	  for	  amplification	  and	  identification	  of	  all	  genotypes.	  Instead,	  we	  chose	  to	  target	  a	  number	  of	  segments	  in	  different	  parts	  of	  the	  genome,	  and	  for	  genotypes	  A-­‐C	  two	   segments	   each	   were	   targeted,	   to	   obtain	   reliable	   accuracy.	   Both	   methods	   showed	   high	  accuracy	   and	   concordance	   with	   earlier	   methods,	   adding	   the	   possibility	   to	   identify	   mixed	  infections	  and	  assign	  relative	  proportions	  to	  the	  strains	  in	  the	  mixture.	  Genotype	   impact	   on	   virological	   outcome	  was	   investigated	   after	   9.2	   years	   in	   124	   chronically	  infected	  adults.	  HBV	  DNA	  levels	  declined	  in	  patients	  carrying	  genotype	  A,	  B,	  and	  D,	  among	  whom	  HBeAg	   loss	  was	   observed	   in	   92%.	  Genotype	  A	   and	  D	   showed	  36%	  and	   11%	   loss	   of	  HBsAg.	   In	  contrast,	  viral	  activity	  and	  aminotransferase	  elevation	  persisted	  in	  genotype	  C	  infections.	  	  In	   the	   final	   study,	   real-­‐time	   PCR	  was	   used	   to	   analyse	   the	   levels	   of	   cccDNA	   and	   viral	   RNA	   in	  biopsies	   and	   cell	   lines	   with	   focus	   on	   differences	   between	   HBeAg	   positive	   and	   negative	   stage.	  Patients	  negative	   for	  HBeAg	  had	  2.15	   log	   lower	   levels	  of	   cccDNA	   in	   liver	   tissue,	  4.84	   log	   lower	  serum	   levels	   of	   HBV	   DNA	   and	   1.45	   log	   lower	   serum	   levels	   of	   HBsAg,	   than	   HBeAg-­‐positive	  patients.	   The	   pgRNA	   in	   liver	   tissue	   correlated	   strongly	   with	   cccDNA	   (R2=0.87)	   and	   HBV	   DNA	  levels	  in	  serum	  (R2=0.81).	  The	  S-­‐RNA/pgRNA	  ratio	  was	  higher	  in	  HBeAg-­‐negative	  patients,	  which	  may	   reflect	   specific	   down-­‐regulation	   of	   pgRNA,	   or	   enhanced	   S-­‐RNA	   production.	   Transcription	  efficiency	   was	   lower	   in	   vitro	   than	   in	   biopsies,	   and	   was	   not	   influenced	   by	   HBV	   core	   promoter	  mutations	  in	  transfected	  Huh7.5	  cells.	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